Sarah Boyce - 17 Dec 2025 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Signature
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
17 Dec 2025
Net transactions value
-$1,131,378
Form type
4
Filing time
19 Dec 2025, 08:27:38 UTC
Previous filing
05 Sep 2025
Next filing
09 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boyce Sarah President and CEO, Director C/O AVIDITY BIOSCIENCES, INC., 3020 CALLAN RD., SAN DIEGO /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact 19 Dec 2025 0001629383

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Award $0 +31,000 +10% $0.000000 336,871 17 Dec 2025 Direct F1
transaction RNA Common Stock Tax liability $1,131,378 -15,742 -4.7% $71.87 321,129 17 Dec 2025 Direct F2
transaction RNA Common Stock Gift $0 -29,159 -9.1% $0.000000 291,970 18 Dec 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired upon the vesting of performance-based restricted stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on October 30, 2024. The PSUs were accelerated and settled on December 17, 2025 for tax planning purposes and such shares remain subject to recoupment by the Issuer if the Reporting Person's employment is terminated by the Issuer for cause or by the Reporting Person without good reason.
F2 Represents the number of shares withheld by the Issuer to cover tax withholding in connection with the settlement of PSUs on December 17, 2025.
F3 Represents a gift of shares to a Donor Advised Fund.